MOW-MING HSUChen Y.-JChang Y.-LJENG-YUH KOSheen T.-S.2021-11-182021-11-1819950125-877Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0029144341&partnerID=40&md5=b94e4b61828f797e432a735adda1cce4https://scholars.lib.ntu.edu.tw/handle/123456789/587218We evaluated whether the serum soluble interleukin-2 receptor (sIL-2R) may be a parameter to monitor the efficacy of treatment for nasopharyngeal carcinoma (NPC). There were 177 NPC patients and 24 healthy controls. The level of sIL-2R was measured with a sandwich ELISA kit. Higher levels of sIL-2R than for controls were found in NPC patients before treatment and in patients with distant metastasis (p < 0.001). There was, however, no difference in sIL-2R levels between controls and NPC patients after radiotherapy in relapse-free or in primary relapse. The sIL-2R levels in sequential testing revealed good correlation with clinical response. The sIL-2R levels were found to be elevated when distant metastasis was detected. Two patients had elevated sIL-2R level up to 5 months before clinical detection of metastasis. These results indicate that serial measurements of sIL-2R levels are worthwhile for NPC patients in their clinical course. The sIL-2R level proved to be an adjunct clinical parameter to monitor the efficacy of treatment of NPC.[SDGs]SDG3interleukin 2 receptor; interleukin receptor; adult; aged; article; controlled study; disease course; enzyme linked immunosorbent assay; female; human; major clinical study; male; metastasis; nasopharynx carcinoma; treatment outcome; Adult; Aged; Female; Human; Male; Middle Age; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Prognosis; Receptors, Interleukin-2; Retrospective Studies; Support, Non-U.S. Gov't; Treatment Outcome; Tumor Markers, Biologicaljournal article74883372-s2.0-0029144341